PMID- 25696805
OWN - NLM
STAT- MEDLINE
DCOM- 20150427
LR  - 20151119
IS  - 1943-7722 (Electronic)
IS  - 0002-9173 (Linking)
VI  - 143
IP  - 3
DP  - 2015 Mar
TI  - Dual HER2 gene protein assay: focused study of breast cancers with 2+ 
      immunohistochemical expression.
PG  - 451-8
LID - 10.1309/AJCPKIVVW4OBPX6I [doi]
AB  - OBJECTIVES: The combined gene protein assay (GPA) can simultaneously assess HER2 
      gene copy number and protein on a single slide using bright-field microscopy. 
      METHODS: GPA was compared with a fluorescence in situ hybridization (FISH) assay 
      on 50 invasive breast carcinomas with a 2+ score on immunohistochemistry (IHC). 
      RESULTS: The cases were categorized into positive, equivocal, or negative for 
      HER2 gene amplification using the 2013 American Society of Clinical 
      Oncology/College of American Pathologists criteria. This resulted in 82% 
      agreement (41 of 50) between FISH and GPA. In addition, 25 known IHC 3+ breast 
      carcinomas analyzed by GPA showed protein overexpression and clusters of HER2 
      gene consistent with unequivocal amplification, and 22 known IHC-negative cases 
      were negative for HER2 gene amplification by GPA. CONCLUSIONS: Although GPA is an 
      alternative to both IHC and FISH, it may be an unnecessary test for IHC 0/1+/3+ 
      cases. The clinical utility of GPA appears to be similar to other in situ 
      hybridization assays (ie, adjudicator of HER2 status for IHC 2+ cases).
CI  - Copyright(c) by the American Society for Clinical Pathology.
FAU - Li, Zaibo
AU  - Li Z
AD  - From the Magee-Womens Hospital of University of Pittsburgh Medical Center, 
      Pittsburgh, PA, and.
FAU - Dabbs, David J
AU  - Dabbs DJ
AD  - From the Magee-Womens Hospital of University of Pittsburgh Medical Center, 
      Pittsburgh, PA, and.
FAU - Cooper, Kristine L
AU  - Cooper KL
AD  - University of Pittsburgh Cancer Institute Biostatistics Facility, Pittsburgh, PA.
FAU - Bhargava, Rohit
AU  - Bhargava R
AD  - From the Magee-Womens Hospital of University of Pittsburgh Medical Center, 
      Pittsburgh, PA, and rbhargava@mail.magee.edu.
LA  - eng
GR  - P30CA047904/CA/NCI NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PL  - England
TA  - Am J Clin Pathol
JT  - American journal of clinical pathology
JID - 0370470
RN  - 0 (Biomarkers, Tumor)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - *Biomarkers, Tumor/genetics/metabolism
MH  - Breast Neoplasms/genetics/metabolism/*pathology
MH  - Carcinoma, Ductal, Breast/metabolism/*pathology
MH  - Female
MH  - Gene Amplification
MH  - Gene Dosage
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Protein Array Analysis
MH  - *Receptor, ErbB-2/genetics/metabolism
OTO - NOTNLM
OT  - FISH
OT  - GPA
OT  - HER2 gene
OT  - HER2 immunohistochemistry
OT  - IHC score 2+
EDAT- 2015/02/20 06:00
MHDA- 2015/04/29 06:00
CRDT- 2015/02/20 06:00
PHST- 2015/02/20 06:00 [entrez]
PHST- 2015/02/20 06:00 [pubmed]
PHST- 2015/04/29 06:00 [medline]
AID - 143/3/451 [pii]
AID - 10.1309/AJCPKIVVW4OBPX6I [doi]
PST - ppublish
SO  - Am J Clin Pathol. 2015 Mar;143(3):451-8. doi: 10.1309/AJCPKIVVW4OBPX6I.